News
-
-
-
COMMUNIQUÉ DE PRESSE
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
Lir Life Sciences Corp. announces a new comparative cell-penetrating peptide-based uptake study for GLP/GIP-based obesity therapies, enhancing transdermal delivery options. The study aims to improve treatment adherence and effectiveness for metabolic conditions -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Lir Life Sciences Corp. Formerly Blackbird Critical Metals Corp. Announces Closing of Acquisition of Lir Life Sciences Inc.
Lir Life Sciences Corp. completes acquisition of Lir Inc., resumes trading on CSE under 'SKNY' ticker symbol. Dr. Edward Mills appointed CEO alongside new board and management members
